SMART Observational Study a Critical Step Toward Full Platform Availability
Toronto, Ontario–(Newsfile Corp. – November 16, 2023) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), ( the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, is excited to announce the initiation of their Physician Experience Program – SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation).
SMART is an observational study intended for cancer treating physicians and their staff in the US to gain experience ordering and utilizing the TeloViewSMM assay. With this launch, participating physicians and their care teams have access to […]
Click here to visit source. finance.yahoo.com
See also Mural depicting diversity in the U.S. on display in Denver alongside tour of 1776 musical at DCPA
Powered by Inline Related Posts